Eli Lilly CDR

Eli Lilly CDR is a Canadian Depositary Receipt (CAD Hedged) providing Canadian investors exposure to Eli Lilly and Company, a leading global pharmaceutical firm founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly engages in the discovery, development, manufacture, and sale of innovative prescription medications for humans and animals, spanning key therapeutic areas including diabetes, oncology, immunology, neuroscience, obesity, and mental health. Notable products include insulin (pioneered as the first commercial version in 1923), diabetes treatments like Trulicity, Mounjaro, and Jardiance; obesity medication Zepbound; antidepressants such as Prozac and Cymbalta; antipsychotics like Zyprexa; and psoriasis treatment Taltz. The company has historically innovated with gelatin capsules, quinine for malaria, and contributions to the polio vaccine, while expanding into veterinary products via Elanco. Employing around 47,000 people, Eli Lilly CDR hedges currency risk, enabling CAD-based trading while reflecting the underlying company's significant role in biomedical research and healthcare markets worldwide.